The Centers for Disease Control and Prevention promises better tests are in the works, but the episode points to vulnerabilities in the country’s defense against emerging outbreaks.
Category: fda
Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs
Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.
From Dr. Oz to Heart Valves: A Tiny Device Charted a Contentious Path Through the FDA
The story of MitraClip, a device Dr. Oz helped invent to treat faulty heart valves, is a cautionary tale about the science, business, and regulation of medical technology.
KFF Health News’ ‘What the Health?’: SCOTUS Term Wraps With a Bang
The Supreme Court has issued its final opinions for the 2023-24 term, including decisions affecting abortion access, the opioid epidemic, and how the federal government functions. In this special episode, Sarah Somers , legal director of the National Health Law Program, joins KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss how the justices disposed of the term’s health-related cases and what those decisions could mean going forward.
The Supreme Court Just Limited Federal Power. Health Care Is Feeling the Shockwaves.
A Supreme Court ruling restricting federal power will likely have seismic ramifications for health policy. A flood of litigation — with plaintiffs like small businesses, drugmakers, and hospitals challenging regulations they say are too expensive or burdensome and not authorized by law — could leave the country with a patchwork of disparate health regulations.
KFF Health News’ ‘What the Health?’: SCOTUS Ruling Strips Power From Federal Health Agencies
In what will certainly be remembered as a landmark decision, the Supreme Court has overruled a 40-year-old precedent that gave federal agencies, rather than judges, the power to interpret ambiguous laws passed by Congress. Administrative experts say the decision will dramatically change the way key health agencies do business. Also, the court decided not to decide whether a federal law requiring hospitals to provide emergency care overrides Idaho’s near-total ban on abortion. Alice Miranda Ollstein of Politico, Victoria Knight of Axios, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
KFF Health News’ ‘What the Health?’: SCOTUS Rejects Abortion Pill Challenge — For Now
The Supreme Court has dismissed a challenge to the FDA’s approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of KFF Health News, and Emmarie Huetteman of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF’s new “Health Policy 101” primer.
KFF Health News’ ‘What the Health?’: Nursing Home Staffing Rules Prompt Pushback
The nursing home industry — as well as a healthy number of Congress members — are all pushing back on the Biden administration’s new rules on nursing home staffing. Industry officials say that there are not enough workers to meet the requirements and that the costs would be prohibitive. Meanwhile, Democrats on Capitol Hill are trying to force Republicans to explain their exact positions on assuring access to contraceptives and in vitro fertilization. Rachel Cohrs Zhang of Stat, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Bram Sable-Smith, who reported and wrote the latest KFF Health News-NPR “Bill of the Month” feature about a free cruise that turned out to be anything but.
KFF Health News’ ‘What the Health?’: Waiting for SCOTUS
June is when the Supreme Court typically issues rulings in the major cases it hears during that year’s term. This year, those interested in health policy are awaiting decisions in two abortion-related cases and one that could reshuffle the way health policies (and all other federal policies) are made. In this special episode, KFF’s Laurie Sobel, associate director for women’s health policy, joins Julie Rovner for a review of the cases and a preview of how the court might rule.
Psychoactive Drugs Are Having a Moment. The FDA Will Soon Weigh In.
Mounting evidence suggests psychoactive drugs including LSD, ketamine, mushrooms, and MDMA can be powerful treatments for severe depression and PTSD. But not everyone is convinced. And even if such drugs gain FDA approval, safety protocols could render them extremely expensive.
